Asset
Bezetabart Debotansine
Sutro Biopharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03424603 | phase1 | completed | 2018-02-22 | 2024-02-15 | Sutro Biopharma, Inc. | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies |
FDA applications (0)
This company has no applications containing this asset.